Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 May;101(3):e327-e337.
doi: 10.1111/aos.15272. Epub 2022 Oct 18.

The comparison of two different strategies of intravitreal conbercept for polypoidal choroidal vasculopathy in Chinese patients results from a 48-week randomized phase 4 study: STAR study

Xiaoxin Li  1   2 , Jinfeng Qu  2 , Guanfang Su  3 , Suqin Yu  4 , Yongjin Zhang  5 , Srini Vas Sadda  6   7 ; STAR Study Group
Affiliations
Free article
Clinical Trial

The comparison of two different strategies of intravitreal conbercept for polypoidal choroidal vasculopathy in Chinese patients results from a 48-week randomized phase 4 study: STAR study

Xiaoxin Li et al. Acta Ophthalmol. 2023 May.
Free article

Abstract

Purpose: To compare a treat-and-extend (TAE) strategy with a fixed dosing regimen of intravitreal conbercept (IVC) for the management of treatment-naïve polypoidal choroidal vasculopathy (PCV) patients.

Methods: 249 patients with treatment-naïve PCV were randomized 1:1 to fixed dosing regimen with injections every 12 weeks (3 + Q12W) group or treat-and-extend regimen(3 + TAE) group. Patients received 3 monthly intravitreal injections of 0.5 mg conbercept as loading dose in both groups. The 3 + Q12W patients were monitored monthly and received mandated injections every 12 weeks; the 3 + TAE patients were monitored and treated monthly until the resolution of exudative disease activity; the interval between visits was then individualized according to study protocol. Visual and anatomical outcomes were compared between the two groups.

Results: At 48 weeks, there was no significant difference between the 3 + Q12W group and 3 + TAE group in mean BCVA improvement (p = 0.421), mean changes in central retinal thickness (CRT) (p = 0.818), maximum retinal thickness (MRT) (p = 0.448), pigment epithelial detachment (PED) height (p = 0.221), PED volume (p = 0.076), branching vascular network (BVN) area (p = 0.615), polypoidal lesion number (p = 0.701), polypoidal lesion area (p = 0.424), rates of patients who avoided vision loss of ≥15 ETDRS letters (p = 0.397) or complete polypoidal lesion regression rate (43.8% vs. 41.8%, p = 0.814). The 3 + Q12W group had more decreased retinal haemorrhage area (p = 0.014) and fewer mean numbers of injections comparing with 3 + TAE group (6.6 vs. 9.4, p < 0.001). Mean maximum extension interval between injections after loading injections was 9.6 ± 2.0 weeks for 3 + TAE group, with 27.8% of patients achieving an extension interval of 12 weeks and 61.1% patients 8 weeks or more.

Conclusions: Both 3 + Q12W and 3 + TAE regimens of IVC could result in improvement in visual and anatomical outcomes in PCV patients.

Keywords: anti-VEGF; conbercept; polypoidal choroidal vasculopathy; treat-and-extend.

PubMed Disclaimer

References

REFERENCES

    1. Chaikitmongkol, V., Sagong, M., Lai, T.Y.Y., Tan, G.S.W., Ngah, N.F., Ohji, M. et al. (2021) Treat-and-extend regimens for the Management of Neovascular age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina society. Asia Pacific Journal of Ophthalmology (Phila), 10, 507-518.
    1. Chan, E.W., Eldeeb, M., Lingam, G., Thomas, D., Bhargava, M. & Chee, C.K. (2017) Quantitative changes in pigment epithelial detachment area and volume predict retreatment in polypoidal choroidal vasculopathy. American Journal of Ophthalmology, 177, 195-205.
    1. Cheng, Y., Shi, X., Qu, J.F., Zhao, M.W. & Li, X.X. (2016) Comparison of the 1-year outcomes of Conbercept therapy between two different angiographic subtypes of polypoidal choroidal vasculopathy. Chinese Medical Journal, 129, 2610-2616.
    1. Cheung, C.M.G., Lai, T.Y.Y., Ruamviboonsuk, P., Chen, S.J., Chen, Y., Freund, K.B. et al. (2018) Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology, 125, 708-724.
    1. Cheung, G.C.M., Lai, T.Y.Y., Gomi, F., Ruamviboonsuk, P., Koh, A. & Lee, W.K. (2017) Anti-VEGF therapy for neovascular AMD and polypoidal choroidal vasculopathy. Asia Pacific Journal of Ophthalmology (Phila), 6, 527-534.

Publication types

Substances